Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04420754 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 30, 2025 (before its estimated August 4, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 4 of 4 sites
    v17
  2. Site contacts updated at 1 of 4 sitesv16
  3. Enrollment target: 30 to 70v15 Show 6 more changesShow less
    • Primary completion date: Jun 28, 2024 to Aug 4, 2026
    • Primary endpoints revised (3)
    • Study completion date: Dec 2024 to Aug 4, 2030
    • Eligibility criteria expanded, about 7 words
    • Site contacts updated at 1 of 4 sites
    • Study arms: 6 to 7
  4. Primary completion date: Sep 28, 2023 to Jun 28, 2024v14
  5. Primary endpoints: 2 to 3v13 Show 7 more changesShow less
    • Enrollment target: 24 to 30
    • Study sites: 3 to 4
    • Primary completion date: Dec 2023 to Sep 28, 2023
    • Eligibility criteria expanded, about 82 words
    • Secondary endpoints: 5 to 1
    • Study arms: 4 to 6
    • Study description expanded, about 4 words
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 2 to 3
    • Study title expanded, about 3 words
    v12
  2. Site details revised at 1 of 2 sitesv11
  3. Primary endpoints revised (2)v10 Show 5 more changesShow less
    • Primary completion date: Jul 2023 to Dec 2023
    • Study completion date: Jul 2024 to Dec 2024
    • Eligibility criteria expanded, about 244 words
    • Secondary endpoints revised (5)
    • Study description expanded, about 10 words
  4. Primary endpoints revised (2)v9 Show 4 more changesShow less
    • Study sites: 1 to 2
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints revised (5)
    • Study description expanded, about 2 words
  5. Primary completion date: Jun 2023 to Jul 2023
    • Study completion date: Jun 2024 to Jul 2024
    • Study description shortened, about 261 words
    • Collaborators shortened, about 6 words
    v8
  6. Re-verified, no change to tracked fieldsv7
  7. Start date: Sep 11, 2020 to Sep 28, 2020v6
  8. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2020 to Sep 11, 2020
    • Site details revised
    v5
  9. Eligibility criteria revisedv4
  10. Lead sponsor: Weill Medical College of Cornell University to AffyImmune Therapeutics, Inc.
    • Collaborator revised
    v3
  11. Study title shortened, about 2 wordsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
Trial Details
NCT Number NCT04420754
Lead Sponsor AffyImmune Therapeutics, Inc.
Conditions
(from sponsor)		 Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Related terms Recurrence, Thyroid Carcinoma, Anaplastic
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov